| NDC Code | 70461-421-10 |
|---|
| Package Description | 1 VIAL, MULTI-DOSE in 1 CARTON (70461-421-10) > 5 mL in 1 VIAL, MULTI-DOSE (70461-421-11) |
|---|
| Product NDC | 70461-421 |
|---|
| Product Type Name | VACCINE |
|---|
| Proprietary Name | Flucelvax Quadrivalent |
|---|
| Proprietary Name Suffix | (multi-dose Vial) |
|---|
| Non-Proprietary Name | Influenza A Virus A/washington/19/2020 (h1n1) Antigen (mdck Cell Derived, Propiolactone Inactivated), Influenza A Virus A/tasmania/503/2020 (h3n2) Antigen (mdck Cell Derived, Propiolactone Inactivated), Influenza B Virus B/darwin/7/2019 Antigen (mdck Cell Derived, Propiolactone Inactivated), Influenza B Virus B/singapore/inftt-16-0610/2016 Antigen (mdck Cell Derived, Propiolactone Inactivated) |
|---|
| Dosage Form | INJECTION, SUSPENSION |
|---|
| Usage | INTRAMUSCULAR |
|---|
| Start Marketing Date | 20200702 |
|---|
| End Marketing Date | 20220731 |
|---|
| Marketing Category Name | BLA |
|---|
| Application Number | BLA125408 |
|---|
| Manufacturer | Seqirus Inc. |
|---|
| Substance Name | INFLUENZA A VIRUS A/TASMANIA/503/2020 (H3N2) ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED); INFLUENZA A VIRUS A/WASHINGTON/19/2020 (H1N1) ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED); INFLUENZA B VIRUS B/DARWIN/7/2019 ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED); INFLUENZA B VIRUS B/SINGAPORE/INFTT-16-0610/2016 ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED) |
|---|
| Strength | 15; 15; 15; 15 |
|---|
| Strength Unit | ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL |
|---|